The oral drug, amcenestrant, was tested with Pfizer’s approved breast cancer drug palbociclib, but the combination didn’t “meet the prespecified boundary for continuation,” according to an Aug. 17 press release.
Physicians will transition the study participants who took the combination to receiving other treatments or palbociclib and letrozole, another breast cancer drug.
The company said it would share the data in the future.
